Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
82 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05329766 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies(EDGE-Gastric) | active not recruiting | Phase 2 | 332 | Arcus Biosciences, Inc.INDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT05914831 | Ultra-hypofractionated Irradiation of the Whole Breast (WBI) Compared to Partial Breast Irradiation (PBI) | active not recruiting | Phase 2 | 106 | Oncology Institute of VojvodinaOTHER_GOV |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT06448754 | Volrustomig Priming Regimens Exploratory Phase II Platform Study(eVOLVE-01) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT06414954 | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis(SYNAPSE-MG) | recruiting | Phase 2 | 84 | NMD Pharma A/SINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | active not recruiting | Phase 2 | 200 | Mirati Therapeutics Inc.INDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)(MAGIC) | active not recruiting | Phase 2 | 65 | Dianthus TherapeuticsINDUSTRY | 14 | Jul 27, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 244 | Karyopharm Therapeutics IncINDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT05661578 | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors(SKYSCRAPER-11) | completed | Phase 2 | 64 | Hoffmann-La RocheINDUSTRY | 9 | Jun 18, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | active not recruiting | Phase 2 | 375 | BicycleTx LimitedINDUSTRY | 21 | May 27, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT05156125 | VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | terminated | Phase 2 | 213 | Oppilan Pharma LtdINDUSTRY | 14 | Apr 30, 2026 | clinicaltrials |
| NCT03315364 | Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy(OPTIMAL) | active not recruiting | Phase 2 / Phase 3 | 549 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 5 | Apr 1, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07250750 | A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis(Synergy-MG) | recruiting | Phase 1 / Phase 2 | 96 | ImmunAbs Inc.INDUSTRY | 6 | Feb 11, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT03760003 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | completed | Phase 2 | 355 | Abivax S.A.INDUSTRY | 17 | Nov 28, 2025 | clinicaltrials |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)(E7080-G000-231) | completed | Phase 2 | 127 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Oct 3, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT04891809 | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | active not recruiting | Phase 2 | 198 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Apr 10, 2025 | clinicaltrials |
| NCT02902029 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(ImmunoCobiVem) | completed | Phase 2 | 186 | University Hospital, EssenOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | terminated | Phase 2 | 70 | Alexion Pharmaceuticals, Inc.INDUSTRY | 8 | Jan 9, 2025 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT03204279 | PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting(CINV) | completed | Phase 2 | 67 | Helsinn Healthcare SAINDUSTRY | 4 | Jun 25, 2024 | clinicaltrials |
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT00036868 | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03826628 | Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | completed | Phase 2 / Phase 3 | 107 | Dermatology Specialties Limited PartnershipINDUSTRY | 9 | Sep 8, 2023 | clinicaltrials |
| NCT04159805 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | completed | Phase 2 | 36 | TakedaINDUSTRY | 6 | Jun 2, 2023 | clinicaltrials |
| NCT04920617 | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(VITALIZE) | recruiting | Phase 2 | 102 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 10 | Apr 7, 2023 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | completed | Phase 2 | 43 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Jun 6, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
Data updated 11 hours agoSource updated unknownsource: clinicaltrials